Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational

Xin Wang1,2, Xi Li1,3, Jing Zhou1,2

  • 1School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, China.

Insights

Regulatory B cells (Bregs) in non-small cell lung cancer (NSCLC) may amplify immunotherapy resistance. Understanding these inducible Bregs and their tumor microenvironment interactions is key to overcoming resistance to immune checkpoint inhibitors (ICIs).

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality globally.
  • Immune checkpoint inhibitors (ICIs) have improved outcomes but face resistance.
  • Current resistance models focus on T cells, overlooking B cell roles.

Purpose of the Study:

  • To propose regulatory B cells (Bregs) as inducible states, not fixed lineages, in NSCLC.
  • To explore how Bregs contribute to immunotherapy resistance in NSCLC.
  • To reframe resistance mechanisms beyond T cell-centric models.

Main Methods:

  • Literature review and synthesis of current research on B cells and immunotherapy resistance.
  • Analysis of the role of tumor microenvironment and spatial context (e.g., tertiary lymphoid structures) in Breg function.
  • Examination of Breg interactions with other immunosuppressive cells.

Main Results:

  • Breg-associated states in NSCLC are inducible and influenced by tumor conditions and spatial context.
  • These Breg states can amplify resistance to ICIs by restraining anti-tumor immunity.
  • Bregs interact with other immunosuppressive populations within the tumor microenvironment.

Conclusions:

  • Regulatory B cells (Bregs) represent inducible states that contribute to immunotherapy resistance in NSCLC.
  • Understanding Breg dynamics and tumor microenvironment interactions is crucial for developing new therapeutic strategies.
  • Future strategies should be biomarker-guided, functionally selective, and spatially informed to overcome resistance.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...